Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA-b-PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.

[1]  L. Johansson,et al.  Fluorescence and Absorption Spectroscopic Properties of Dipyrrometheneboron Difluoride (BODIPY) Derivatives in Liquids, Lipid Membranes, and Proteins , 1994 .

[2]  M. Bally,et al.  The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  R. Vile,et al.  Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Y. Sugiyama,et al.  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Weissleder,et al.  Imaging inflammation of the pancreatic islets in type 1 diabetes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Wahl,et al.  Cellular Dynamics Visualized in Live Cells in Vitro and in Vivo by Differential Dual-Color Nuclear-Cytoplasmic Fluorescent-Protein Expression , 2004, Cancer Research.

[7]  Colleen A Crane,et al.  Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  K. Avgoustakis,et al.  Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. , 2005, International journal of pharmaceutics.

[9]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[10]  R. Schwendener,et al.  Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach , 2006, British Journal of Cancer.

[11]  Meng Yang,et al.  Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. , 2007, Cancer research.

[12]  G. Soma,et al.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[13]  R. Weissleder,et al.  Utility of a new bolus-injectable nanoparticle for clinical cancer staging. , 2007, Neoplasia.

[14]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[15]  A. Koch.  The pathogenesis of rheumatoid arthritis. , 2007, American journal of orthopedics.

[16]  M. Amiji,et al.  Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. , 2007, Journal of pharmaceutical sciences.

[17]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[18]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[19]  G. Jung,et al.  Comparative photostability studies of BODIPY and fluorescein dyes by using fluorescence correlation spectroscopy. , 2008, Chemphyschem : a European journal of chemical physics and physical chemistry.

[20]  Anthony Harriman,et al.  The chemistry of fluorescent bodipy dyes: versatility unsurpassed. , 2008, Angewandte Chemie.

[21]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[22]  M. Czech,et al.  Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation , 2009, Nature.

[23]  Sujay Chattopadhyay,et al.  Polymer- and liposome-based nanoparticles in targeted drug delivery. , 2010, Frontiers in bioscience.

[24]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[25]  Robert Langer,et al.  Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy , 2010, Proceedings of the National Academy of Sciences.

[26]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[27]  Cui Tang,et al.  Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.

[28]  F. Ginhoux,et al.  Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.

[29]  K. Moore,et al.  Macrophages in the Pathogenesis of Atherosclerosis , 2011, Cell.

[30]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[31]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[32]  Omid C Farokhzad,et al.  Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo , 2011, Proceedings of the National Academy of Sciences.

[33]  Ralph Weissleder,et al.  Analysis of mitosis and antimitotic drug responses in tumors by in vivo microscopy and single-cell pharmacodynamics. , 2011, Cancer research.

[34]  J. Brenton,et al.  Evolution of platinum resistance in high-grade serous ovarian cancer. , 2011, The Lancet. Oncology.

[35]  W. Zamboni,et al.  Interpatient Pharmacokinetic and Pharmacodynamic Variability of Carrier‐Mediated Anticancer Agents , 2012, Clinical pharmacology and therapeutics.

[36]  Jae-Hyun Park,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[37]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[38]  Ran Kafri,et al.  Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. , 2012, Molecular cell.

[39]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[40]  Daniel G. Anderson,et al.  Origins of tumor-associated macrophages and neutrophils , 2012, Proceedings of the National Academy of Sciences.

[41]  R. Langer,et al.  Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. , 2013, ACS nano.

[42]  Robert Langer,et al.  Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug , 2013, Proceedings of the National Academy of Sciences.

[43]  Christina S. Leslie,et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.

[44]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[45]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[46]  Greg M. Thurber,et al.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo , 2013, Nature Communications.

[47]  Robert Langer,et al.  Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. , 2012, Nanomedicine.

[48]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[49]  Z. Gu,et al.  The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy. , 2013, Biomaterials.

[50]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[51]  H. Tsuchiya,et al.  Imaging UVC‐induced DNA damage response in models of minimal cancer , 2013, Journal of cellular biochemistry.

[52]  Jianghong Rao,et al.  Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. , 2014, Small.

[53]  Miles A. Miller,et al.  Platinum Compounds for High‐Resolution In Vivo Cancer Imaging , 2014, ChemMedChem.

[54]  Ralph Weissleder,et al.  Imaging windows for long-term intravital imaging , 2014, Intravital.

[55]  Ralph Weissleder,et al.  Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor , 2014, Scientific Reports.

[56]  M. Nahrendorf,et al.  Cardiac macrophages and their role in ischaemic heart disease. , 2014, Cardiovascular research.

[57]  Jessica Wright.  Nanotechnology: Deliver on a promise , 2014, Nature.

[58]  Jessica Wright.  Deliver on a promise. , 2014, Scientific American.

[59]  F. Hazard,et al.  Cancer Therapy: Development of Novel Tumor‐Targeted Theranostic Nanoparticles Activated by Membrane‐Type Matrix Metalloproteinases for Combined Cancer Magnetic Resonance Imaging and Therapy (Small 3/2014) , 2014 .

[60]  Linda G. Griffith,et al.  Molecular Network Analysis of Endometriosis Reveals a Role for c-Jun–Regulated Macrophage Activation , 2014, Science Translational Medicine.

[61]  R. Weissleder,et al.  Imaging macrophages with nanoparticles. , 2014, Nature materials.

[62]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[63]  S. Lippard,et al.  Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery , 2014, Journal of the American Chemical Society.

[64]  Travis M. Shaffer,et al.  Environment-responsive Nanophores for Therapy and Treatment Monitoring via Molecular MRI Quenching , 2014, Nature Communications.

[65]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[66]  E. Winer,et al.  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  Ashley M. Laughney,et al.  Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin , 2014, Science Translational Medicine.

[68]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[69]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[70]  S. Gadde.  Multi-drug delivery nanocarriers for combination therapy , 2015 .

[71]  A META-ANALYSIS OF THE LITERATURE , 2017 .